Why longevity clinics are multiplying
Longevity has moved from academic gerontology to consumer offering with remarkable speed. London now hosts a growing number of clinics selling healthspan assessment and optimisation, and the model is spreading to other UK cities, often layered onto existing private GP, aesthetics or wellness businesses. The commercial logic is straightforward: an ageing, affluent customer base, a subscription-style revenue model, and a scientific field generating genuine excitement and therefore generous benefit of the doubt.
The intellectual backdrop matters too. There is a real and serious research field here, studying cellular ageing, senescence and the biology of age-related disease. The clinics borrow its vocabulary. What they cannot borrow is its results, because with few exceptions the interventions that extend life or healthspan in model organisms have not been shown to do so in humans. The gap between the laboratory and the clinic brochure is the single most useful thing a prospective customer can hold in mind, and it mirrors a pattern we have described elsewhere in aesthetics, where plausible mechanism routinely outruns clinical proof.
What a typical package contains
Offerings vary, but a recognisable stack has emerged across the UK market.
| Tier | Typical contents | Indicative annual cost |
|---|---|---|
| Entry | Blood panel, body composition scan, questionnaire, report and plan | £300, £1,000 |
| Mid | Adds VO2max testing, continuous glucose monitoring, DEXA, wearable integration, follow-up reviews | £1,000, £3,500 |
| Premium | Adds whole-body or targeted MRI, genetic and epigenetic age testing, supplement or peptide protocols, concierge medical access | £3,500, £15,000+ |
The pattern worth noticing is that diagnostic volume rises faster than evidential value as you climb the tiers. The entry tier contains most of the genuinely informative measurement. The premium tiers add tests that are either screening tools with real trade-offs, whole-body MRI in asymptomatic people generates incidental findings and follow-up cascades at a meaningful rate, or measurements whose clinical utility is unestablished.
The interventions with real evidence
The strongest evidence in this field attaches to a short and unfashionable list, and to the clinics' credit, the better ones say so.
Cardiorespiratory fitness, measured properly as VO2max, shows one of the most consistent gradients with all-cause mortality in the epidemiological literature indexed on PubMed, and unlike a genome, it is modifiable. Muscular strength and mass show similar, independent associations, and resistance training is the intervention that changes them. Sleep duration and quality track mortality and metabolic health across large cohorts. Smoking cessation, blood pressure control, lipid management and weight management round out the list, and all are standard medicine with decades of trial evidence, delivered every day by the NHS under NICE guidance, without a membership fee.
A fair summary: a longevity clinic that measures your VO2max, grip strength and blood pressure, then coaches you through training, sleep and diet changes and retests you, is selling something real. It is selling structure, measurement and accountability around interventions the evidence supports. Whether that service is worth the price attached to it is a personal judgement, but the ingredients are legitimate.
The speculative layer
Above that floor sits the layer that generates the headlines and much of the margin, and it deserves plain language.
- Biological age and epigenetic clocks. Genuinely interesting research tools with real correlations at population level. At individual level, different clocks disagree with each other, test-retest variability is significant, and no intervention has been shown to improve hard outcomes by improving a clock score. Selling repeat testing as progress-tracking gets ahead of what these instruments can support.
- Broad unvalidated biomarker panels. Measuring dozens of analytes in a healthy person maximises the probability of incidental abnormalities, each triggering anxiety, retesting and cost, with no demonstrated outcome benefit for untargeted screening of the asymptomatic.
- Peptide protocols. Many peptides marketed for longevity are unlicensed for that purpose in the UK, with human evidence ranging from thin to absent, and quality control of sourced products is a genuine safety concern. Prescribing unlicensed products carries specific professional obligations, and buyers should ask hard questions about them.
- NAD+ infusions and supplement stacks. Precursor supplementation raises blood NAD+ levels. Demonstrated improvement in human health outcomes has not followed, and intravenous delivery adds cost and risk without adding evidence.
In the longevity market, the strength of the evidence and the size of the invoice are usually inversely related.
None of this means the speculative layer is fraudulent. Some of it will mature into medicine, and clinics involved in registered research deserve credit. But a customer should know which layer of the offer each pound is buying, and the brochures rarely draw the line for them.
Regulation: thinner than patients assume
Longevity clinic is a marketing term with no legal definition, a situation directly parallel to the one we documented for the term aesthetic clinic in UK law. Where a clinic employs doctors and performs regulated activities, in England it will fall within scope of the Care Quality Commission, and its doctors answer to the GMC. But much of the longevity stack, fitness testing, wearables, coaching, supplements, sits outside regulated activity entirely, and the diagnostic tests are only as good as the clinical governance interpreting them.
Practical checks for a prospective member: is the clinic CQC-registered, and for what activities; who reviews the results, and what are their qualifications and registration; what happens when a test finds something, is there a defined pathway back into NHS or specialist care; and will they share their evidence for any named protocol in writing. A serious operation answers all four without friction. The commercial trajectory of this sector, in which clinics increasingly resemble subscription technology businesses, is something we examine in our piece on clinics built like tech companies, and the same dynamics apply here, for better and worse.
What a rational buyer would pay for
Strip the offer to what the evidence supports and a rational shape emerges. Pay for accurate measurement of things that are modifiable and predictive: VO2max, strength, blood pressure, standard lipids and glycaemic markers, body composition. Pay, if it helps you, for structured coaching and retesting, because adherence is where most health intentions die. Be sceptical of any test whose result would not change what you do, of any protocol whose evidence cannot be produced in writing, and of any programme whose price is driven by the tier of diagnostics rather than the quality of follow-through.
The deepest irony of the longevity market is that its best-evidenced products, training, sleep, and ordinary preventive medicine, are the cheapest things it sells. A clinic that helps you actually do them is providing a real service. A clinic that sells you an epigenetic age instead is selling you a number, and the number does not yet mean what the brochure implies.
